A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

NCT02973321 on ClinicalTrials.gov · last registry update 2022-03-24

An unusually large phase 2: 296 participants, more than double the 110 typical for the stage. The sponsor logged completion for 27 December 2017. Primary outcome, as filed: Change From Baseline in HbA1c to Week 26. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Sanofi
Sponsor type: Industry
Enrollment: 296
Started: 2016-12-02
Primary completion: 2017-12-27 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in HbA1c to Week 26

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.